Shield Therapeutics plc (STX)
LSE
Closed
Aug 24, 2026
Day's Range
4.7052 wk Range
3.70Overview - STX - Shield Therapeutics plc
Key Statistics
Valuation
Enterprise Value
50.06M
P/E (Forward)
‪6.46‬
PEG Ratio
‪6.46‬
Price / Sales (TTM)
‪0.88‬
EV / EBITDA
‪-16.87‬
Profitability
Profit Margin
‪-17.69%‬
Operating Margin
‪0.68%‬
Return on Assets
‪-4.37%‬
Return on Equity
‪117.09%‬
Ownership
Shares Outstanding
1.06B
Float
412.49M
Held by Insiders
‪61.75%‬
Held by Institutions
‪3.33%‬
Price stats
50-Day Avg
‪5.53‬
200-Day Avg
‪8.11‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - STX - Shield Therapeutics plc
Peers - STX - Shield Therapeutics plc
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on LSE.
- STXLSEShield Therapeutics plc4.70BMarket Cap-52.27%52-week change—P/E (Trailing)‪-35.52%‬Profit Margin
- HLNLSEHaleon plc3.19TMarket Cap+1.46%52-week change20.17P/E (Trailing)‪14.55%‬Profit Margin
- 0QFPLSEGedeon Richter Plc.1.74TMarket Cap+0.00%52-week change18.82P/E (Trailing)‪19.72%‬Profit Margin
- ROSELSERosebank Industries plc342.98BMarket Cap+2.31%52-week change—P/E (Trailing)‪-10.78%‬Profit Margin
- 0MTDLSESwedish Orphan Biovitrum AB167.10BMarket Cap+37.04%52-week change47.34P/E (Trailing)‪15.54%‬Profit Margin
- HCMLSEHUTCHMED (China) Limited154.69BMarket Cap-27.81%52-week change184.00P/E (Trailing)‪3.25%‬Profit Margin
- 0O14LSEMerck KGaA64.01BMarket Cap+20.52%52-week change19.49P/E (Trailing)‪13.95%‬Profit Margin
Profile Summary - STX - Shield Therapeutics plc
About
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company dedicated to developing and commercializing late-stage, hospital-focused pharmaceuticals, primarily addressing iron deficiency in adult patients. Its flagship product, Accrufer® (also known as Feraccru® in certain regions), is an…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
